Key Highlights

  • Loss per share was USD 0.54 against an estimate of a USD 0.47 loss.
  • Collaboration Revenue was USD 3.9 million against an estimate of USD 4.87 million.
  • Net loss was USD 29.94 million, against USD 15.53 million.
  • Cash and marketable securities were USD 492.9 million at September 30.

Aktis Oncology (NASDAQ:AKTS) reported a third quarter 2026 loss per share of USD 0.54, against an estimate of a USD 0.47 loss. Collaboration revenue was USD 3.9 million, against an estimate of USD 4.87 million. Net loss was USD 29.94 million, compared with USD 15.53 million in the third quarter of 2025.

The loss from operations was USD 34.75 million, compared with USD 18.20 million. The company reported the figures in its quarterly filing for the period ended September 30, 2026.

Operating Expenses and Other Income

Research and development expenses were USD 32.13 million, compared with USD 16.47 million. General and administrative expenses were USD 6.53 million, compared with USD 3.32 million. Total operating expenses were USD 38.65 million, compared with USD 19.78 million.

Other income, net, was USD 4.8 million, compared with USD 2.7 million, and the filing attributes the USD 2.1 million increase primarily to higher interest income from higher average balances in cash equivalents and marketable securities. Interest income was USD 4.82 million, compared with USD 2.68 million.

Nine-Month Results

For the nine months ended September 30, 2026, net loss was USD 72.41 million, compared with USD 48.59 million, and the loss per share was USD 1.36. Total operating expenses were USD 96.87 million, compared with USD 61.94 million, and the loss from operations was USD 86.35 million, compared with USD 57.31 million.

Research and development expenses for the nine months were USD 77.44 million, compared with USD 50.96 million, and general and administrative expenses were USD 19.43 million, compared with USD 10.98 million. Share-based compensation for the nine months was USD 9.69 million, compared with USD 4.03 million.

Liquidity and Collaboration

The company believes that its existing cash, cash equivalents and marketable securities of USD 492.9 million as of September 30, 2026 are sufficient to allow it to fund operations for at least twelve months from the date the financial statements are issued.

The filing describes a collaboration agreement entered into in May 2024 with Eli Lilly and Company to generate anticancer radiopharmaceuticals using the company's miniprotein technology platform. It also describes the 2026 Equity Incentive Plan and the 2026 Employee Stock Purchase Plan, each adopted in January 2026 and effective on January 8, 2026, and notes that the company is advancing AKY-2519 into clinical trials.

The Balance Sheet reports total liabilities of USD 73.61 million, an accumulated Deficit of USD 228.97 million and total stockholders' equity of USD 458.87 million. For the nine months, net cash used in Operating Activities was USD 70.88 million and net cash provided by financing activities was USD 339.41 million. The filing states that the company has incurred losses since inception, including net losses of USD 72.4 million and USD 48.6 million for the nine months ended September 30, 2026 and 2025, respectively.

Aktis Oncology Q3 2026 Earnings: Key Takeaways

Aktis Oncology reported a third quarter 2026 loss per share of USD 0.54 and a net loss of USD 29.94 million. Research and Development expenses were USD 32.13 million, and cash, cash equivalents and marketable securities were USD 492.9 million.